Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Virtual reality could ease symptoms during intensive blood cancer treatment

NCT ID NCT07649512

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a virtual reality headset for guided muscle relaxation can help people undergoing cell therapies like CAR-T or stem cell transplant feel better. Participants will use the VR headset once daily for up to 20 minutes during their hospital stay. Researchers will measure how practical this approach is and whether it improves symptoms like pain, anxiety, and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Progressive Muscle Relaxation delivered via Virtual Reality
What this could lead to
If it works, this could offer a drug-free way to reduce anxiety, pain, and other symptoms during intensive cancer therapy.
What could go wrong
This is a small feasibility study, so it may not prove whether VR relaxation actually improves symptoms. The effect may be limited by patients' ability to use the headset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to provide informed consent 2. Age greater than or equal to 18 years old 3. Either have a planned admission or already be admitted to the in-patient oncology ward (3NW) with cellular therapy needs. 4. Able to understand English 5. Able to sit-up in bed or bedside chair space to utilize VR device at the time of enrollment 6. Able to utilize VR device and computer/laptop to access necessary resources for participation 7. Performance Status as defined by European Cooperative Oncology Group (ECOG) score of 0-2 Exclusion Criteria: 1. Poor performance status of ECOG 3-4 2. Recent use of immersive VR programs for stress relief and/or entertainment (more than 2 days/week within the past 3 months) 3. Participation in another stress-reduction type interventional study within the past 3 months 4. Current or history of seizure, epilepsy, or other known severe neurological or mental health disorders 5. Clinical Sensitivity to flashing light or motion or having balance disorders previously diagnosed 6. Having another medical condition or co-morbidity that may prevent use of VR program or physical materials (e.g., visual or hearing problems, open sores, wounds, skin rash on face, or active infection) 7. Patients with concern for neurotoxicity or acute treatment related neurological issues such as ICANS. ICANS grade 1 maybe eligible to re-enter trial. ICANS grade 2 or greater would be permanently excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heme malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Arizona

    Tucson, Arizona, 85719, United States